Knapp DC - Search Results

1

Fluoride-cleavable, fluorescently labelled reversible terminators: synthesis and use in primer extension.

Knapp DC, Serva S, D'Onofrio J, Keller A, Lubys A, Kurg A, Remm M, Engels JW. Knapp DC, et al. Chemistry. 2011 Mar 1;17(10):2903-15. doi: 10.1002/chem.201001952. Epub 2011 Feb 3. Chemistry. 2011. PMID: 21294195 Free PMC article.

2

Synthesis of four colors fluorescently labelled 3'-O-blocked nucleotides with fluoride cleavable blocking group and linker for array based Sequencing-by-Synthesis applications.

Knapp DC, Keller A, D'Onofrio J, Lubys A, Serva S, Kurg A, Remm M, Kwiatkowski M, Engels JW. Knapp DC, et al. Nucleic Acids Symp Ser (Oxf). 2008;(52):345-6. doi: 10.1093/nass/nrn174. Nucleic Acids Symp Ser (Oxf). 2008. PMID: 18776395

3

Fluorescent labeling of (oligo)nucleotides by a new fluoride cleavable linker capable of versatile attachment modes.

Knapp DC, D'Onofrio J, Engels JW. Knapp DC, et al. Bioconjug Chem. 2010 Jun 16;21(6):1043-55. doi: 10.1021/bc900542f. Bioconjug Chem. 2010. PMID: 20509599

4

The fluoride cleavable 2-(cyanoethoxy)methyl (CEM) group as reversible 3'-O-terminator for DNA sequencing-by-synthesis - synthesis, incorporation, and cleavage.

Földesi A, Keller A, Stura A, Zigmantas S, Kwiatkowski M, Knapp D, Engels JW. Földesi A, et al. Nucleosides Nucleotides Nucleic Acids. 2007;26(3):271-5. doi: 10.1080/15257770701257301. Nucleosides Nucleotides Nucleic Acids. 2007. PMID: 17454736

5

Electrospun polydioxanone-elastin blends: potential for bioresorbable vascular grafts.

Sell SA, McClure MJ, Barnes CP, Knapp DC, Walpoth BH, Simpson DG, Bowlin GL. Sell SA, et al. Among authors: knapp dc. Biomed Mater. 2006 Jun;1(2):72-80. doi: 10.1088/1748-6041/1/2/004. Epub 2006 May 4. Biomed Mater. 2006. PMID: 18460759

6

Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in a Lewis lung carcinoma murine model.

Knapp DC, Mata JE, Reddy MT, Devi GR, Iversen PL. Knapp DC, et al. Anticancer Drugs. 2003 Jan;14(1):39-47. doi: 10.1097/00001813-200301000-00006. Anticancer Drugs. 2003. PMID: 12544257

7

Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats.

Arora V, Knapp DC, Reddy MT, Weller DD, Iversen PL. Arora V, et al. Among authors: knapp dc. J Pharm Sci. 2002 Apr;91(4):1009-18. doi: 10.1002/jps.10088. J Pharm Sci. 2002. PMID: 11948540

8

Opportunistic testing of medically underserved women for cervical cancer in South Africa.

van Bogaert LJ, Knapp DC. van Bogaert LJ, et al. Among authors: knapp dc. Acta Cytol. 2001 May-Jun;45(3):313-6. doi: 10.1159/000327624. Acta Cytol. 2001. PMID: 11393060

9

c-Myc antisense limits rat liver regeneration and indicates role for c-Myc in regulating cytochrome P-450 3A activity.

Arora V, Knapp DC, Smith BL, Statdfield ML, Stein DA, Reddy MT, Weller DD, Iversen PL. Arora V, et al. Among authors: knapp dc. J Pharmacol Exp Ther. 2000 Mar;292(3):921-8. J Pharmacol Exp Ther. 2000. PMID: 10688605

10

Cytological screening for cervical cancer--what are its opportunity costs?

van Bogaert LJ, Knapp DC. van Bogaert LJ, et al. Among authors: knapp dc. S Afr Med J. 1997 May;87(5):618-9; author reply 619-20. S Afr Med J. 1997. PMID: 9254828 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

10 results

Search Page

Filters